MSB $1 Party, page-347

LOL OMG WOW....The guru of pump at his finest!!

"To this end, I have been doing more work on the availability of cells from MSB's prospective upgrades to manufacturing, and I included a number of speculative calculations in my last note - this is a major change - analysts don't yet have these upgrades to yields, number of cells possible to manufacture and big drop in manufacturing costs.

I think it is quite possible that MSB will be able to produce 25,000 treatments by the end of the March quarter 2021 and rising to 100,000 treatments pa by Dec 2021. Then they can survey the requirements and decide if more manufacturing is required, but I think it will be as they begin to expand into non-Covid ARDS. Eventually, if this all works, I can see MSB providing a steady state 200,000 treatments per year for non-Covid and Covid-19 ARDS combined. At a price of $US70k per treatment, that could generate royalties in three years of $US4.2 billion pa and net profits (after US tax) of $A4.66 billion - put that on a P/E of 30 and that's a $A140 billion company - or $A224 per share in 3 years - you should then discount that back to today's value at whatever rate you think appropriate to give a valuation today - let's say 15%, giving a value now of around $A150 - just for ARDS."